Patient-friendly, non-technical summary of research papers

September 2026 Research Update

This report covers research on Eosinophilic fasciitis published in PubMed in September 2026. For other months, see all research updates.

Last update: October 10, 2026

At a glance

Blood eosinophils

Normal blood eosinophils did not exclude EF.

MRI findings

MRI showed inflamed, thickened fascia when biopsy was not done.

Steroid-based treatment

Both case reports described improvement after steroid-based treatment.

Unusual EF patterns

This month included two case reports where EF resembled an abscess or systemic sclerosis. Diagnosis depended on deep tissue findings or MRI, and the reports cannot show what works best for most people.

Overview

This month’s eosinophilic fasciitis (EF) research was limited to two individual case reports. The main change is a clearer picture of how EF can show up in less typical ways in real life.

One report described EF that looked like a recurring leg abscess after minor trauma. Antibiotics did not help and cultures were sterile. A deep tissue biopsy showed fibrosis with many eosinophils, even though blood eosinophils were normal. This supports the idea that a normal eosinophil count in blood does not rule out EF.

The other report described EF affecting the hands and fingers in a way that resembled systemic sclerosis. Key systemic sclerosis clues were missing. MRI showed thickened and inflamed fascia. This added practical support for MRI as a way to strengthen the diagnosis when a full-thickness biopsy is not feasible.

Both people improved after treatment that included corticosteroids (steroids). One case also used mycophenolate and tocilizumab and described improved hand function. These reports add context about what EF can look like and what outcomes may be followed, but they cannot show which tests or treatments work best for most people.

Get the monthly update by email

Subscribe here to receive an email when a new monthly eosinophilic fasciitis update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month only case reports were published, and both highlighted how eosinophilic fasciitis (EF) can be hard to recognize when it does not follow the usual pattern. In one person, EF looked like a recurring leg abscess after minor trauma, and in another, EF affected the fingers in a way that resembled systemic sclerosis. Together, these reports add a clearer picture that EF can be localized, can involve the hands, and may not show the expected blood eosinophilia.

One report described a 16-year-old with a red, warm, abscess-like leg swelling where antibiotics did not help and cultures were sterile, which pushed the workup away from infection. A deep skin and subcutaneous tissue biopsy showed fibrotic tissue with many eosinophils, supporting EF even though MRI was not done and fascia involvement was not definitively confirmed on biopsy. This shows that EF can still be considered even when blood eosinophils are normal and the presentation is very localized.

The other report described a 48-year-old with overlap autoimmune disease who developed hand and finger stiffness that mimicked systemic sclerosis, but key systemic sclerosis clues were missing (no Raynaud phenomenon, normal nailfold exam, and negative systemic sclerosis antibodies). MRI showed inflamed and thickened fascia, and a full-thickness biopsy was deferred. This report adds to the idea that MRI can sometimes provide important supportive evidence for EF when biopsy is not feasible.

For patients and caregivers, this month mainly adds practical understanding rather than changing care right now, because the evidence comes from 2 individual cases. The reports reinforce that EF can be mistaken for other problems like infection or systemic sclerosis, and that normal blood eosinophil counts do not rule it out. They also show that different kinds of evidence may be used to support the diagnosis, such as MRI findings of fascia inflammation or biopsy findings of eosinophils and fibrosis, depending on what is possible in a given situation. What remains uncertain is how often these less typical presentations happen and which tests are most reliable across people, since single cases cannot answer those questions.

Both individuals improved after EF-directed treatment, but the treatments were not the same and the reports do not allow conclusions about which medicines work best. One patient improved with systemic corticosteroids, and the other improved in function and mobility with a combination of prednisone, mycophenolate, and tocilizumab, with skin findings described as stable at 18 months. This is most useful as early, real-world context about the range of EF presentations and the types of follow-up outcomes that can be tracked (such as hand closure, grip, walking, and skin stability).

Limitations

This month’s evidence came only from two single-person case reports.
Case reports cannot show how often these presentations happen across people.
Case reports cannot tell which tests or medicines work best overall.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.